SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    FlemingID, CooperJS, HensonDE, HutterRVP, KennedyBJ, MurphyGP, et al, editors. American Joint Committee on Cancer staging manual. 5th edition. Philadelphia: Lippincott-Raven Publishers, 1997.
  • 2
    NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990; 264: 1444-50.
  • 3
    Francini G, Petrioli R, Lorenzini R, et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994; 106: 899-906.
  • 4
    Wolmark N, Raced H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993; 11: 1879-87.
  • 5
    O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15: 246-50.
  • 6
    IMPACT Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939-44.
  • 7
    Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-10.
  • 8
    GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA 1994; 271: 1587-92.
  • 9
    Cronbach LJ, Warrington WG. Time-limit tests: estimating their reliability and degree of speeding. Psichometrika 1951; 314: 1657-64.
  • 10
    Likert R. A technique for the measurement of attitudes. Arch Psychol 1932; 140: 5-55.
  • 11
    Drummond M, Stoddardt G, Torrance G. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1987.
  • 12
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
  • 13
    Tarone RI, Ware J. On distribution-free tests for equality of survival distributions. Biometrika 1977; 64: 156-60.
  • 14
    Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34: 187-202.
  • 15
    Zaniboni A. Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and 5-fluorouracil: impact on disease-free survival and overall survival. J Clin Oncol 1997; 15: 2432-41.
  • 16
    Wolmark N, Rockette H, Mamounas EP, et al. The relative efficacy of 5-FU-leucovorin (FU-LV), 5-FU-levamisole(FU-Lev), and 5-FU-leucovorin-levamisole in patients with Dukes B and C carcinoma of the colon: first report of NSABP C-04 [Abstract 460]. Proc Am Soc Clin Oncol 1996; 15: 205.
  • 17
    Haller DG, Catalano PJ, Macdonald JS, et al. Fluorouracil (FU), leucovorin (LV), and levamisole (LEV) adjuvant therapy for colon cancer: preliminary results of INT-0089 [Abstract 486]. Proc Am Soc Clin Oncol 1996; 15: 211.
  • 18
    O'Connell MJ, Laurie JA, Shepherd L, et al. A prospective evaluation of chemotherapy duration and regimens as surgical adjuvant treatment for high-risk colon cancer: a collaborative trial of the North Central Cancer Treatment Group and the National Cancer Institute of Canada Clinical Trials [Abstract 478]. Proc Am Soc Clin Oncol 1996; 15: 209.
  • 19
    Gelber RD, Goldhirsch A, Cole BF, et al. A quality-adjusted time without symptoms or toxicity(Q-TWIST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst 1996; 88: 1039-45.
  • 20
    Mamounas EP, Rockette H, Jones J, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes B vs. C colon cancer: results from four NSABP adjuvant studies (C-01, C-02, C-03, C-04) [Abstract 461]. Proc Am Soc Clin Oncol 1996; 15: 205.